metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
versus non active control
	avelumab alone
	A-Brave, 2024 Journal of Clinical Oncology NCT02926196	RCT	es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)	avelumab	control	Patiennts at High-risk Triple Negative Breast Cancer after completion of standard treatment with curative intent including surgery and neoadjuvant/adjuvant chemotherapy.	-/-	NA	suggested	suggested 34 % decrease in deaths (OS) inconclusive 18 % decrease in RFS/DFS (PE) inconclusive 19 % decrease in RFS/DFS (PE) One year adjuvant avelumab versus control does not significantly improve DFS in high-risk TNBC patients. Nevertheless, the secondary enpoind OS was significanlty improved with avelumab vs control.

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

NCT02926196

RCT

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

avelumab

control

Patiennts at High-risk Triple Negative Breast Cancer after completion of standard treatment with curative intent including surgery and neoadjuvant/adjuvant chemotherapy.

-/-

suggested 34 % decrease in deaths (OS)
inconclusive 18 % decrease in RFS/DFS (PE)
inconclusive 19 % decrease in RFS/DFS (PE)

One year adjuvant avelumab versus control does not significantly improve DFS in high-risk TNBC patients. Nevertheless, the secondary enpoind OS was significanlty improved with avelumab vs control.

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)

versus non active control

avelumab alone